Jeffrey V. Matous, MD, discusses how telehealth and remote monitoring can enhance the safe administration of bispecific ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Jeffrey V. Matous, MD, discusses how primary barriers to the widespread use of bispecific antibody therapies in community ...

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.

Jeffrey V. Matous, MD, discusses how best practices in transitioning care between academic and community centers can enhance patient outcomes when receiving bispecific antibodies, and the critical ...

Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer ...

In patients with HIV, alcohol reduction after a 6-month intervention and adherence to isoniazid had no effect on the high ...

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

Young patients with cancer residing in historically redlined areas face a significantly higher risk of mortality, ...

The renewal for the ninth straight year includes McKesson's latest measure for resolution of health-related social needs.

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...